• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PharmaJet, Vaccibody collaborate on needle-free HPV vaccine

October 25, 2016 By Sarah Faulkner

Vaccibody, PharmaJetPharmaJet and Vaccibody inked a collaborative deal to provide needle-free injection tech for the development of a human papillomavirus vaccine.

HPV is the cause of virtually all cervical cancer, according to the National Cancer Institute, and just 2 types of HPV, 16 and 18, are responsible for about 70% of all cases.

PharmaJet’s device is designed to administer medication intramuscularly or subcutaneously, without the use of needles. The Chicago-based company touts the technology as a way to prevent cross-contamination between needles and enhance patient compliance.

“The Phase I clinical data showed that not only does the vaccine appear to have an excellent safety profile, but the T-cell immune responses observed show that our vaccine (VB10.16) induces the strongest HPV16-specific immune response we have seen reported in the literature,” Vaccibody CEO Martin Bonde said in prepared remarks. “While other DNA vaccines developed for this indication require delivery with in vivo electroporation, which is quite painful for the patients, VB10.16 is delivered by needle-free injection, which we believe improves patient compliance tremendously and will be a significant asset in further development of this product.”

“We are pleased that the PharmaJet device is being used for this important study, and are encouraged by the improved compliance that needle-free may provide. This is consistent with our survey data that shows 93% of patients would choose needle-free again for their next vaccination,” added PharmaJet chairman & CEO Ron Lowy. “Given that multiple vaccine doses are required for the HPV vaccine, improved compliance with needle-free is an important advantage.”

In August, PharmaJet landed a multi-year partnership with the World Health Organization as part of the group’s effort to eradicate polio using the company’s needle-free tech.

Filed Under: Drug-Device Combinations, Featured, Research & Development Tagged With: PharmaJet, Vaccibody

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Reader Interactions

Comments

  1. Mh ayub hussain says

    March 23, 2019 at 9:16 pm

    Hi i need more info detail for above said products.can it be used for circum.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS